Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Clinical Results - Allogeneic Matched Related Donor Transplantation Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire

Mohamad Mohty, MD, PhD1, Le Quoc-Hung2*, Franck E Nicolini, MD, PhD3, Frederic Garban, MD4*, Gerard Socie5*, Michel Attal, MD6*, Noel-Jean Milpied, PhD7, Bruno Lioure, MD8*, Pierre Bordigoni, MD9, Ibrahim Yakoub-Agha, MD, PhD10, Jean-Henri Bourhis11*, Bernard Rio12*, Eric Deconinck13, Marc Renaud, MD14*, Jean-Luc Harousseau15, Didier Blaise, MD16 and Mauricette Michallet, MD17*

1Hematology Dept., CHU de Nantes, Nantes, France
2CHU de Lyon, Lyon, France
3Hematology Department, Hospital E. Herriot, Lyon, France
4Hopital Michallon - SFGMTC, Grenoble, France
5Haematology, Hopital Saint-Louis
6Hopital Purpan - SFGMTC, Toulouse, France
7Hopital Haut Leveque - Pessac, Pessac, France
8Département d'Hématologie et d'Oncologie, CHU Hautepierre, Strasbourg, France
9Hopital D'Enfants Medecine Infantile 2 - SFGMTC, Vandoeuvre, France
10Maladies du Sang, UAM Allogreffes de CSH - EA2686, Lille, France
11Inst. Gustave-Roussy, Paris, France
12Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, Paris, France
13Hematology, INSERM UMR645 - CHU Jean Minjoz, Besançon
14Hopital La Mileterie - SFGMTC, Poitiers, France
15Hôpital Hôtel Dieu, Nantes, France
16Institut Paoli Calmettes, Marseille, France
17Hopital E. Herriot - SFGMTC, Lyon

Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up

Avichai Shimoni*, Avital Rand*, Izhar Hardan*, Noga Shem-Tov*, Yulia Volchek*, Ronit Yerushalmi* and Arnon Nagler

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

Higher Absolute NK Count on Day30 after HLA Identical Sibling Allogeneic Stem Cell Transplantation and a “Favorable KIR” Genotype Are Associated with Faster NK Maturation and Other Functional Differences

David Z. Drew, MD1, Jan Melenhorst, Ph.D2*, Nancy F. Hensel, Ph.D3* and A. John Barrett, MD, FRCP4

1BMT, NIH/NCI, Bethesda, MD
2Nhlbi, NIH, Bethesda, MD
3Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD
4NHLBI, NIH, Bethesda, MD

Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)Clinically Relevant Abstract

Armand Keating, MD1, Manisha Kukreja, MBBS, MPH2*, Gisela Tunes da Silva, PhD3*, Vikas Gupta, MD, MRCP, MRCPath1, Corey Cutler, MD, MPH4, Martin S. Tallman, MD5, Jorge Sierra, MD6, John F. DiPersio, MD, PhD7*, Mary M. Horowitz, MD, MS2 and Daniel J. Weisdorf, MD8

1Princess Margaret Hospital, Toronto, ON, Canada
2Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
3Medical College of Wisconsin, Milwaukee, WI
4Dana-Farber Cancer Inst., Boston, MA
5Northwestern University Feinberg School of Medicine, Chicago, IL
6Hospital De Sant Pau, Barcelona, Spain
7Washington University School of Medicine, St. Louis, MO
8University of Minnesota, Minneapolis, MN

Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA)

Vikas Gupta, MD, MRCP, MRCPath1, Jeanette Carreras, MPH2*, Ruta Bajorunaite, PhD2*, Robert Peter Gale, MD, PhD, DSc3, Mitchell Sabloff, MDCM, FRCPC, MSc4, Mahmoud Aljurf, MD5*, Hubert Schrezenmeier, MD6, Gerard Socié, MD7*, Jakob Passweg, MD, MS8, Olle Ringdén, MD9*, Ricardo Pasquini, MD10*, Judith Marsh, MD11 and Mary Eapen, MBBS12

1Princess Margaret Hospital, Toronto, ON, Canada
2Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
3Celgene Corp., Summit, NJ
4Ottawa Hospital, Ottawa, ON, Canada
5King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
6Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
7Hopital Saint-Louis, Paris, France
8Hopitaux Universitaires de Geneve, Geneve, Switzerland
9Karolinska Institutet, Stockholm, Sweden
10Universidade Federal do Paraná, Curitiba, Brazil
11King's College Hospital, London, United Kingdom
12Medical College of Wisconsin, Milwaukee, WI

Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)

Leslie Andritsos1*, Mehdi Hamadani1*, Nyla A. Heerema, PhD2, Don Benson1, Craig C. Hofmeister, MD3*, William Blum, MD2, Joseph Flynn1*, Jeffrey Alan Jones, MD4, Patrick Elder1*, Thomas S. Lin1*, Gerard Lozanski1*, John C. Byrd1* and Steven Devine1

1Division of Hematology/Oncology, Ohio State University, Columbus, OH
2Ohio State University, Columbus, OH
3Hematology and Oncology, Ohio State University, Columbus, OH
4Ohio State University Medical Center, Columbus, OH

Updated Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem Cell Transplantation

Shigeki Ohtake, MD1, Shuichi Miyawaki, MD2, Hiroyuki Fujita, MD2, Hitoshi Kiyoi, MD2, Katsuji Shinagawa, MD2*, Noriko Usui, MD2*, Kohichi Miyamura, MD2*, Miki Nishimura, MD2*, Yasushi Miyazaki, MD2, Kazuhiro Nishii, MD2*, Tadashi Nagai, MD2, Takahisa Yamane, MD2*, Masafumi Taniwaki, MD2*, Masatomo Takahashi, MD2*, Fumiharu Yagasaki, MD2*, Yukihiko Kimura, MD2*, Norio Asou, MD2, Sumihisa Honda, Ph.D.2*, Kazunori Ohnishi, MD2*, Tomoki Naoe, MD2 and Ryuzo Ohno, MD2*

1Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
2Japan Adult Leukemia Study Group, Japan

Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Shubham Pant, M.D.1*, Sayed Mehdi Hamadani, MD2, Pamela Crilley, DO3*, Jeffrey Szer4, Anthony J. Dodds, FRACP, FRCPA5, Dustin E. Stevenson, DO6*, Gary Phillips2*, Patrick Elder7*, Ian Nivison-Smith5*, Belinda Avalos8, Sam Penza2*, David Topolsky3*, R. Sobecks9, Matt Kalaycio, MD9, Brian J. Bolwell, MD9 and Edward Copelan9

1Health Sciences Center, University of Oklahoma, Oklahoma City, OK
2Hematology/Oncology, The Ohio State Univ., Columbus, OH
3Division of Hematology/Oncology, Drexel University College of Medicine, Philadelphia, PA
4Clinical Haematology & BMT Service, The Royal Melbourne Hospital, Parkville, Australia
5St. Vincent's Hospital Sydney Ltd., Sydney, NSW, Australia
6Hematology - Medical Oncology, Lackland Air Force Base, Lackland AFB, TX
7Division of Hematology/Oncology, Ohio State University, Columbus, OH
8Medicine, Division of Hematology/Oncology, Heart and Lung Research Institute, The Ohio State University, Columbus, OH
9Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCTClinically Relevant Abstract

Khaled M Ramadan, MB1, Kevin W. Song2*, Joseph M. Connors3*, Abdul Al-Tourah3*, Randy D. Gascoyne4*, Michael J. Barnett2*, Stephen H. Nantel, MD, FRCPC5, Thomas J. Nevill, MD, FRCPC6, John D. Shepherd, MD6, Heather J. Sutherland, MD, PhD5, Julye Lavoie, MD6, Donna L. Forrest2*, Donna E. Hogge, MD, PhD7, Nicholas Voss, MD8*, Ryan Brinkman, PhD7*, Yasser R. Abou Mourad2*, Maryse M. Power2*, Sujaatha Narayanan2, Clayton A. Smith9* and Cynthia L. Toze, MD, FRCP(C)2

1Hematology, St. Paul's Hospital, Vancouver, BC, Canada
2Hematology, Leukemia/BMT Program of BC, Vancouver, BC, Canada
3Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
4Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
5Vancouver General Hospital, Vancouver, BC, Canada
6Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver, BC, Canada
7B.C. Cancer Research Center, Vancouver, BC, Canada
8Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC
9Leukemia/BMT Program of BC, Vancouver, BC, Canada

Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin

Robert Lowsky, MD, Judith Shizuru, MD, PhD*, Stephan Busque, MD*, John Scandling, MD*, Minnie Sarwal, MD*, Sussan Jones*, Claudia Benike*, Richard Hoppe, MD*, Ed Engleman, MD* and Sam Strober, MD*

Stanford University Medical Center, Stanford, CA

*signifies non-member of ASH